205 related articles for article (PubMed ID: 28445193)
21. Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Park DH; Chung JK; Seo DR; Lee SJ
Am J Ophthalmol; 2016 Mar; 163():122-131.e2. PubMed ID: 26685791
[TBL] [Abstract][Full Text] [Related]
22. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Stevenson W; Sadrai Z; Hua J; Kodati S; Huang JF; Chauhan SK; Dana R
Cornea; 2014 Feb; 33(2):177-83. PubMed ID: 24342887
[TBL] [Abstract][Full Text] [Related]
23. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
24. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
25. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
Stevenson D; Tauber J; Reis BL
Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
[TBL] [Abstract][Full Text] [Related]
28. Ocular surface evaluation in allogenic hematopoietic stem cell transplantation patients.
Vanathi M; Kashyap S; Khan R; Seth T; Mishra P; Mahapatra M; Tandon R
Eur J Ophthalmol; 2014; 24(5):655-66. PubMed ID: 24604604
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
[TBL] [Abstract][Full Text] [Related]
31. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
32. Tear Osmolarity and Ocular Surface Parameters as Diagnostic Markers of Ocular Graft-Versus-Host Disease.
Na KS; Yoo YS; Hwang KY; Mok JW; Joo CK
Am J Ophthalmol; 2015 Jul; 160(1):143-9.e1. PubMed ID: 25870935
[TBL] [Abstract][Full Text] [Related]
33. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
Nichols JJ; Bickle KM; Zink RC; Schiewe MD; Haque RM; Nichols KK
Eye Contact Lens; 2012 Mar; 38(2):73-9. PubMed ID: 22157392
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
36. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
37. Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment.
Johnson ME; Murphy PJ; Boulton M
Optom Vis Sci; 2008 Aug; 85(8):750-7. PubMed ID: 18677239
[TBL] [Abstract][Full Text] [Related]
38. A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease.
Zallio F; Mazzucco L; Monaco F; Astori MR; Passera R; Drago G; Tamiazzo S; Rapetti M; Dolcino D; Guaschino R; Pini M; Ladetto M
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1664-1670. PubMed ID: 27269196
[TBL] [Abstract][Full Text] [Related]
39. A plethora of ocular surface manifestations in a multidisciplinary ocular graft-versus-host disease unit.
Trindade M; Rodrigues M; Pozzebon ME; Aranha FJP; Colella MP; Fernandes A; Fornazari DO; de Almeida Borges D; Vigorito AC; Alves M
Sci Rep; 2022 Sep; 12(1):15926. PubMed ID: 36151252
[TBL] [Abstract][Full Text] [Related]
40. Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgery.
Mencucci R; Boccalini C; Caputo R; Favuzza E
J Cataract Refract Surg; 2015 Aug; 41(8):1699-704. PubMed ID: 26432128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
